中藥材黃連併用於惡性腫瘤放射線治療之輔助性功能研究

成佳憲
國立台灣大學醫學
腫瘤放射線治療過程中如何增強腫瘤細胞對放射線治療的感受性，與減低對正常組織的損傷，是極需解決的兩大問題。發炎反應是目前被研究認為同時與這兩個問題有最大關聯性的生理反應，也就是放射線治療引發的發炎反應可能對腫瘤細胞有利，但卻對正常組織有害。這樣的理論已經逐漸被接受，並已有利用抗發炎藥物與放射線治療併用的臨床測試進行中。在中藥材中亦有許多被公認具有良好抗發炎效果的藥材，這些藥材事實上業已經過數百甚至數千年的人體安全性試驗，以長期服用的考量上，其副作用可能比西藥更小，因此只要再予以科學性的研究建立適切的理論基礎，將對於運用於腫瘤輔助性放射治療有很大的發展潛力。本計畫所提之黃連在傳統上及現代的研究中都被證實具有抗腫瘤、抗血管新生、抗發炎、殺菌等作用。學理上而言，十分適合運用於抑制腫瘤放射線治療引發的發炎反應，與感染的輔助性治療。本計畫所提出之中藥材黃連，除了最重要的安全性，也具有社會大眾熟知的普遍性，且具備取得方便，經濟實惠等特點。再者黃連組成份的明確性，使得其作用機轉與藥理作用得以被科學性的驗証，放射線治療為臨床腫瘤治療中安全性最高的非侵入性治療方式。
關鍵字：黃連；放射線治療；腫瘤

Adjunct therapeutic effect of Chinese herb Coptis chinensis in combination with radiotherapy on cancer

Jason Chia-Hsien Cheng
National Taiwan University Hospital and National Taiwan University College of Medicine
According to the Chinese traditional therapy, Coptis chinensis is used as an anti-inflammatory herb. In recent researches, Coptis chinensis was also found that it has anti-tumor property in animal model. We investigated the theraputic effect of Coptis chinensis on human cancer while accepting radiotherapy. Coptis chinensis and its extracts and pure components were used to test in hepatoma cancer cell lines HepG2, Hep3B and cervical cancer cell lines SiHa, HeLa. The prelimit-result showed that Coptis chinensis and its extracts under nontoxicity concentration, could (1) couse both hepatoma cancer and cervical cancer cell lines cell cycle arrest significantly, (2) attenuated the serum-induced invasion in both hepatoma cancer and cervical cancer cell lines, (3) decreased the angiogenic effect of hepatoma cancer and cervical cancer cell lines on CAM and HUVEC tube formation (4) slow down the tumor growth rate of HeLa in mouse model. Furthermore, we are going to analysis the mechanism of Coptis chinensis and its extracts on human cancer cell lines by DNA microarray. Result from this present study suggested that Coptis chinensis and its extracts did have the therapy potential on human cancer.
關鍵字：Coptis chinensis；radiotherapy；cancer